Genomic Vision: drawdown of two new tranches for € 2 million as part of the financing program concluded with Winance – 12/24/2021 at 6:00 p.m.


It is recalled that in the context of a press release dated June 15, 2020, the Company announced the signing of an issue contract on June 11, 2020 with Winance with a view to setting up a line financing by issuance of convertible bonds (the “OC”) into ordinary shares to each of which will be attached a share subscription warrant (the “BSA” and together with the shares to which they are attached the “ABSA” and with the OC the “OCABSA”), for a maximum total amount of 12 million euros. The extraordinary general meeting of shareholders of the Company which met on October 30, 2020 approved the implementation of this financing.

Terms of the transaction
Using the delegation of authority granted to it by the extraordinary general meeting of shareholders, the management board decided to issue 2,000 OCABSAs for a total amount of 2 million euros for the benefit of Winance or any affiliated entity. (the “Investor”).
The CB must be subscribed by the Investor within ten (10) working days following the decision of the management board, if the usual conditions of the request are met.

The gross proceeds of the transaction will therefore be 2 million euros and the net proceeds of 1.9 million euros.



Source link -86